Basilea Pharmaceutica - Cresemba IV formulation approved in China
Basilea has announced the approval in China of the intravenous (IV) formulation of Cresemba, the company’s antifungal drug, for treating adult patients with invasive aspergillosis and invasive mucormycosis. The oral formulation of Cresemba is already approved in China where it is marketed by Basilea’s licence partner in the region, Pfizer. We see approval of the IV formulation as a positive development for Basilea; in 2021 China accounted for 19% of the global antifungal drug market, second only to the United States. However, we continue to see inclusion of Cresemba on the National Reimbursement Drug List (NRDL) in China as key to unlocking the full value of the Chinese market. We expect Basilea to benefit from the considerable experience of Pfizer in navigating the NRDL inclusion process for Cresemba. We continue to value Basilea Pharmaceutica at CHF847.7m or CHF71.6/share.Basilea Pharmaceutica is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of bacterial infections, fungal infections, oncology and skin diseases. Co. focuses on antibiotics and antifungals as well as oncology and dermatology drugs. Co.'s portfolio spans from innovative early-stage through clinical late-stage drug candidates to a marketed product. In the context of its international commercialization organization, Co. has subsidiaries in Denmark, France, Germany, Italy, Spain and the United Kingdom.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.